Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the tumor marker testing market?

Recent years have seen substantial growth in the size of the tumor marker testing market. It’s projected to expand from its 2024 size of $17.18 billion to $18.6 billion by 2025, indicating a compound annual growth rate (CAGR) of 8.3%. Various factors, including a rise in cancer cases, an intensified emphasis on research and development, an increase in public understanding of cancer screening procedures, advances in healthcare infrastructure, and an aging demographic, have contributed to this historic growth.

What will be the tumor marker testing market size in the future?

In the years to come, a substantial expansion is projected for the tumor marker testing market. The predicted growth is to $25.27 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this surge during the forecast period include heightened awareness about proactive cancer detection, escalated funding for cancer-related studies, the growth of personalized medicine, amplified healthcare spending, and enhanced insurance coverage. Technological progression, novel products, development in diagnostic techniques, cutting-edge testing methods, and a rise in strategic partnerships are among the principal trends expected during the forecast period.

Get your tumor marker testing market report here!

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

What main drivers are fueling expansion in the tumor marker testing market?

The tumor marker testing market’s growth is predicted to be driven by the rising prevalence of cancer. Cancer, defined by unregulated growth of abnormal cells which can invade nearby tissues or spread via the blood or lymph systems, is becoming more prevalent due to factors such as aging populations, increased environmental exposures, lifestyle alterations, and enhanced detection and diagnosis. Tumor marker testing, which measures specific substances produced by cancer cells, is employed for diagnosing, monitoring treatment responses, and spotting recurrences in various cancer types. For example, the American Cancer Society, a non-profit organization based in the US, reported in January 2023 that America had 1,958,310 new cancer instances and 609,820 cancer-related deaths. Additionally, the National Library of Medicine, another US-based entity, stated in May 2021 that by 2040, the worldwide cancer burden is projected to reach 28.4 million cases reflecting a 47% increase from 2020, with a high death toll. This escalating prevalence of cancer is hence escalating the demand for tumor marker testing market.

What key areas define the segmentation of the global tumor marker testing market?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Other Products

2) By Methods: Screening, Imaging, Theranostics, Sigmoidoscopy, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2/neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Who are the dominant players expanding their reach in the tumor marker testing market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

How are evolving market trends shaping tumor marker testing Strategies?

Leading enterprises within the tumor marker testing industry are putting their efforts into the development of innovative tests such as molecular testing solutions in a bid to establish a unique standing in the market. The term molecular testing solutions is used to describe progressive diagnostic methods that scrutinize genetic material (DNA or RNA) to identify mutations, pathogens, or unique biomarkers at a molecular level. For example, Onco-D-clare, a pioneering cancer detection test, was introduced by Switzerland-based company, RGCC International GmbH, which specializes in personalized cancer treatment, in April 2024. This revolutionary test allows early detection of cancer before any symptoms emerge, by harnessing the power of molecular biology and artificial neural networks. The function of Onco-D-clare involves separating peripheral blood mononuclear cells from blood samples, followed by a thorough gene expression analysis of over 90 genes.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20668

Which regions are emerging as leaders in the tumor marker testing market?

North America was the largest region in the tumor marker testing market in 2024. The regions covered in the tumor marker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cancer Tumor Profiling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Circulating Tumor Cells Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: